Thursday, November 12, 2026
ExploreSearch
Via News
MarketIndexes

Nikkei 225 Bullish Momentum With A 6% Jump In The Last 21 Sessions

Nikkei 225 Bullish Momentum With A 6% Jump In The Last 21 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 6.97% for the last 21 sessions. At 21:08 EST on Thursday, 11 July, Nikkei 225 (N225) is $41,418.50.

Regarding Nikkei 225's yearly highs and lows, it's 35.85% up from its 52-week low and 1.12% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was 0.80%, 0.42%, and 0.83%, respectively.

Nikkei 225's highest amplitude of average volatility was 0.96% (last week), 0.77% (last month), and 0.83% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be oversold (<=20).

News about

  • According to Zacks on Wednesday, 10 July, "It may not seem this way, as the six-straight up-days on the S&P 500 and Nasdaq indices have been very modestly incremental. "

More news about Nikkei 225 (N225).

Categories

MarketIndexes

Tags

IndexWorld IndicesIndicesN225Nikkei 225Price UpINDICES Price UpIndex Nowintelligent
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com